Share this video  

ASCO GI 2023 | Addressing resistance to ICIs in colorectal cancer

Heinz-Josef Lenz, MD, FACP, University of Southern California, Los Angeles, CA, describes strategies to enhance the efficacy of immune checkpoint inhibitors (ICIs) in patients with colorectal cancer, especially in those with immunologically cold tumors. STING agonists have shown clinical activity in early stage clinical trials, and TIM-3 and LAG-3 have been identified as potential therapeutic targets. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Gastrointestinal Cancers (GI) Symposium in San Francisco, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.